386
Views
19
CrossRef citations to date
0
Altmetric
Original Article

Clinical course of Crohn’s disease during the first 5 years. Results from a population-based cohort in Sweden (ICURE) diagnosed 2005–2009*

, , , , &
Pages 81-86 | Received 04 May 2016, Accepted 24 Aug 2016, Published online: 15 Sep 2016
 

Abstract

Objective: The aim of the study was to describe the medical treatment, change in phenotype, need for surgery and IBD-associated mortality during the first 5 years after diagnosis.

Material and Methods: Patients diagnosed with Crohn’s disease including all age groups in the Uppsala healthcare region in the middle of Sweden 2005–2009 were included in the study. Medical notes were scrutinised and patients contacted. Out of 269 patients, 260 (96.3%) could be followed for 5 full years or until death.

Results: The following drugs were used: 5-ASA 66.7%, systemic steroids 76.4%, antimetabolites 56.7% and anti-TNF 20.3%. Described with the Montreal classification, the proportion with inflammatory behaviour decreased from 78.1% to 74.0% from diagnosis to end of the observation, patients with stricturing behaviour increased from 13.0% to 15.4% and patients with penetrating behaviour increased from 8.9% to 10.6%. After the first year, 12.4% had been treated with intestinal resection or colectomy, a figure that increased to 14.8 after 5 years. Two patients suffered an IBD-related death.

Conclusions: Compared to similar patient cohorts, the present study demonstrates that although the course of Crohn’s disease seems difficult to change during the first year after diagnosis, the following years up to 5 years shows a more benign course than has usually been described earlier.

Acknowledgements

All authors read and approved the final manuscript.

Disclosure statement

The authors have no competing interests to declare.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.